Diseases of the Nervous System (Second Edition), 2021, Pages 81-107
This book chapter advances SDG #3 and #10 by introducing the basic foundation of aging, dementia and Alzheimer Disease, including clinical presentation, diagnosis and epidemiology.
The Sendai Framework for Disaster Risk Reduction (SFDRR) has helped to reduce global disaster risk, but there has been a lack of progress in disaster risk reduction (DRR) for people living in fragile and conflict affected contexts (FCAC). Given the mounting evidence that DRR cannot be implemented through conventional approaches in FCAC, serious efforts must be made to understand how to meet SFDRR's goals.
Little is known about the immediate psychological impacts of the national lockdown implemented during the COVID-19 pandemic on the general population in Arab countries like Jordan. The aim of this study was to assess the levels of depression, coping skills, and quality of life and their correlates among a sample of Jordanian adults aged ≥18 years during the COVID-19 lockdown implemented in Jordan.
Alzheimer's disease (AD) is the commonest neurodegenerative disorder with a wide array of manifestations, courses, and contributing causes. Despite being clinically characterized a long time ago; no treatment has been developed that could improve the pathology or slow down the disease manifestation- so far. Indian Catechu methanolic extract (ICME) has proved to have multiple beneficial effects that support its use in several disorders- especially those with complex etiology.
This book chapter advances SDG #3 and #10 by providing therapeutic strategies that can be employed in clinical trials for AD in DS will be discussed as well as their underlying scientific rationale.
This book chapter advances SDG #3 and #10 by providing a brief history of PET imaging and the radiotracers that have had a significant impact for measuring the three signature AD-related neuropathologies related to AD and provides an overview of the research utilizing PET imaging in the DS population
This book chapter advances SDG #3 and #10 by discussing the advantages of performing genetic studies in people with DS, and then discussing the role of reported genes that are known to be associated with AD risk in adults with DS or in the general population. It also discusses how future longitudinal multiomic and imaging study can enhance our understanding of the biology of AD.
Elsevier,
Alzheimer’s Disease: Understanding Biomarkers, Big Data, and Therapy, Volume , 1 January 2021
This book chapter advances SDG #3 and #10 by discussing the operational aspects of deep learning solutions for Alzheimer’s disease, including the review of the advantages and limitations of using deep learning, and future directions on the applications of deep learning to Alzheimer’s disease.
This book chapter advances SDG #3 and #10 by systematically appraises the concepts and promising benefits of AI technology within healthcare for AD risk prediction across communities, and its possible concerns to be tackled prior to large-scale implementation.
Elsevier,
Alzheimer’s Disease: Understanding Biomarkers, Big Data, and Therapy, Volume , 1 January 2021
This book chapter advances SDG #3 and #10 by providing evidence that behavioral treatments are more effective than most pharmacological therapies at managing depression in Alzheimer’s disease.
